+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 70Years +
All Genders
ID06108414

Comparing Low-Dose and Standard-Dose Rivaroxaban for Treating Atrial Fibrillation in Patients Aged 70 and Older

Led by China National Center for Cardiovascular Diseases · Updated on 2024-09-19

4374

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of low-dose versus standard-dose rivaroxaban anticoagulation therapy in elderly patients with atrial fibrillation. This Phase 4 randomized study focuses on patients aged 70 years and older who have atrial fibrillation and a CHA2DS2-VASc score indicating moderate to high stroke risk. The goal is to compare these dosing strategies to better understand their impact on cardiovascular and cerebrovascular events. Participants are randomly assigned to one of two groups the low-dose group receives 15 mg of rivaroxaban daily, which may be reduced to 10 mg daily for certain conditions such as reduced kidney function, low body weight, or age 80 and above the standard-dose group receives 20 mg daily, with dose reductions to 15 mg under the same conditions. Treatment lasts for approximately two years following randomization, with adherence to dosing guidelines based on individual health factors. During the study, participants will be monitored for major adverse cardiovascular and cerebrovascular events over about two years. Researchers will also track bleeding events, overall clinical benefits, and other related health outcomes. Assessments include regular clinical evaluations, safety monitoring, and follow-up visits to ensure patient well-being and gather data on the effects of both dosing regimens throughout the study period.

CONDITIONS

Brief Title

Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation

Research Team

Z

Zhe Zheng, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here